Medicines For Europe Proposes Revised Remodulation To EU Exclusivity Proposals
Trade Group Believes Market Exclusivity Should Face Incentive Extensions, Not Data Exclusivity
Executive Summary
Medicines for Europe proposed several alterations to the European Commission’s planted alterations to market exclusivity incentives at its recent Regulatory and Pharmacovigilance Conference in Brussels, most prominently that various proposed extensions to data exclusivity should instead be used to extend market exclusivity.